Role of endothelium-derived hyperpolarizing factor in ACE inhibitor-induced renal vasodilation in vivo. 2004

Hiroto Matsuda, and Koichi Hayashi, and Shu Wakino, and Eiji Kubota, and Masanori Honda, and Hirobumi Tokuyama, and Ichiro Takamatsu, and Satoru Tatematsu, and Takao Saruta
Department of Internal Medicine School of Medicine, Keio University, 35 Shinanomachi Shinjuku-ku, Tokyo 160-8582, Japan. khayashi@sc.itc.keio.ac.jp

Although the angiotensin-converting enzyme (ACE) inhibitor-induced bradykinin enhances nitric oxide (NO) release, bradykinin may also stimulate the production of an additional vasodilator, endothelium-derived hyperpolarizing factor (EDHF). This study examined the role of EDHF in mediating the NO-independent action of ACE inhibitors in canine renal microcirculation in vivo. We used intravital CCD camera videomicroscopy that allowed direct visualization of renal microcirculation in superficial and juxtamedullary nephrons in an in vivo, in situ, and relatively intact setting. In the presence of E4177 (an angiotensin receptor blocker), cilazaprilat (30 microg/kg) had no effect on diameter of superficial afferent arterioles (Aff), but it increased renal contents of bradykinin and nitrate plus nitrite, and it elicited dilation of juxtamedullary Aff (from 24.0+/-0.2 to 28.2+/-0.8 microm), juxtamedullary efferent arterioles (Eff) (from 24.2+/-0.2 to 28.0+/-0.8 microm), and superficial Eff (from 18.2+/-0.2 to 19.7+/-0.2 microm). These changes in diameters were prevented by N(alpha)-adamantaneacetyl-d-Arg-[Hyp(3),Thi(5,8),D-Phe(7)]bradykinin, a bradykinin receptor antagonist. The pretreatment with nitro-l-arginine methylester (l-NAME) plus E4177 eliminated the dilator response of juxtamedullary/superficial Eff and the increase in renal nitrate plus nitrite levels induced by cilazaprilat. In contrast, in the presence of E4177+l-NAME, cilazaprilat still caused 8%+/-3% dilation of juxtamedullary Aff, which was completely eliminated by proadifen, a cytochrome-P450 and K(Ca) channel blocker. Collectively, the ACE inhibitor exerts multiple vasodilator mechanisms, including the inhibition of angiotensin II formation; blockade of angiotensin II activity appears to be a dominant mechanism in superficial Aff, whereas the bradykinin-induced NO acts on superficial Eff and juxtamedullary Aff/Eff. Furthermore, a putative EDHF is an additional mechanism for the ACE inhibitor-induced vasodilation of juxtamedullary Aff in vivo.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008833 Microcirculation The circulation of the BLOOD through the MICROVASCULAR NETWORK. Microvascular Blood Flow,Microvascular Circulation,Blood Flow, Microvascular,Circulation, Microvascular,Flow, Microvascular Blood,Microvascular Blood Flows,Microvascular Circulations
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D012079 Renal Circulation The circulation of the BLOOD through the vessels of the KIDNEY. Kidney Circulation,Renal Blood Flow,Circulation, Kidney,Circulation, Renal,Blood Flow, Renal,Flow, Renal Blood
D001920 Bradykinin A nonapeptide messenger that is enzymatically produced from KALLIDIN in the blood where it is a potent but short-lived agent of arteriolar dilation and increased capillary permeability. Bradykinin is also released from MAST CELLS during asthma attacks, from gut walls as a gastrointestinal vasodilator, from damaged tissues as a pain signal, and may be a neurotransmitter. Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg,Bradykinin Acetate, (9-D-Arg)-Isomer,Bradykinin Diacetate,Bradykinin Hydrochloride,Bradykinin Triacetate,Bradykinin, (1-D-Arg)-Isomer,Bradykinin, (2-D-Pro)-Isomer,Bradykinin, (2-D-Pro-3-D-Pro-7-D-Pro)-Isomer,Bradykinin, (2-D-Pro-7-D-Pro)-Isomer,Bradykinin, (3-D-Pro)-Isomer,Bradykinin, (3-D-Pro-7-D-Pro)-Isomer,Bradykinin, (5-D-Phe)-Isomer,Bradykinin, (5-D-Phe-8-D-Phe)-Isomer,Bradykinin, (6-D-Ser)-Isomer,Bradykinin, (7-D-Pro)-Isomer,Bradykinin, (8-D-Phe)-Isomer,Bradykinin, (9-D-Arg)-Isomer,Arg Pro Pro Gly Phe Ser Pro Phe Arg
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001685 Biological Factors Endogenously synthesized compounds that influence biological processes not otherwise classified under ENZYMES; HORMONES or HORMONE ANTAGONISTS. Biologic Factors,Biological Factor,Factor, Biologic,Factor, Biological,Factors, Biological,Biologic Factor,Factors, Biologic

Related Publications

Hiroto Matsuda, and Koichi Hayashi, and Shu Wakino, and Eiji Kubota, and Masanori Honda, and Hirobumi Tokuyama, and Ichiro Takamatsu, and Satoru Tatematsu, and Takao Saruta
October 1999, Nihon Jinzo Gakkai shi,
Hiroto Matsuda, and Koichi Hayashi, and Shu Wakino, and Eiji Kubota, and Masanori Honda, and Hirobumi Tokuyama, and Ichiro Takamatsu, and Satoru Tatematsu, and Takao Saruta
December 2013, American journal of physiology. Heart and circulatory physiology,
Hiroto Matsuda, and Koichi Hayashi, and Shu Wakino, and Eiji Kubota, and Masanori Honda, and Hirobumi Tokuyama, and Ichiro Takamatsu, and Satoru Tatematsu, and Takao Saruta
February 2015, Vascular medicine (London, England),
Hiroto Matsuda, and Koichi Hayashi, and Shu Wakino, and Eiji Kubota, and Masanori Honda, and Hirobumi Tokuyama, and Ichiro Takamatsu, and Satoru Tatematsu, and Takao Saruta
January 1990, Blood vessels,
Hiroto Matsuda, and Koichi Hayashi, and Shu Wakino, and Eiji Kubota, and Masanori Honda, and Hirobumi Tokuyama, and Ichiro Takamatsu, and Satoru Tatematsu, and Takao Saruta
January 1998, Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi,
Hiroto Matsuda, and Koichi Hayashi, and Shu Wakino, and Eiji Kubota, and Masanori Honda, and Hirobumi Tokuyama, and Ichiro Takamatsu, and Satoru Tatematsu, and Takao Saruta
January 2000, Nihon rinsho. Japanese journal of clinical medicine,
Hiroto Matsuda, and Koichi Hayashi, and Shu Wakino, and Eiji Kubota, and Masanori Honda, and Hirobumi Tokuyama, and Ichiro Takamatsu, and Satoru Tatematsu, and Takao Saruta
December 1996, Clinical and experimental pharmacology & physiology,
Hiroto Matsuda, and Koichi Hayashi, and Shu Wakino, and Eiji Kubota, and Masanori Honda, and Hirobumi Tokuyama, and Ichiro Takamatsu, and Satoru Tatematsu, and Takao Saruta
November 2003, European journal of pharmacology,
Hiroto Matsuda, and Koichi Hayashi, and Shu Wakino, and Eiji Kubota, and Masanori Honda, and Hirobumi Tokuyama, and Ichiro Takamatsu, and Satoru Tatematsu, and Takao Saruta
December 1992, The Journal of laboratory and clinical medicine,
Hiroto Matsuda, and Koichi Hayashi, and Shu Wakino, and Eiji Kubota, and Masanori Honda, and Hirobumi Tokuyama, and Ichiro Takamatsu, and Satoru Tatematsu, and Takao Saruta
June 2005, Yao xue xue bao = Acta pharmaceutica Sinica,
Copied contents to your clipboard!